Preparation and characterization of PEG-coated silica nanoparticles for oral insulin delivery

Andreani, Tatiana; Souza, Ana Luiza Ribeiro de; Kiill, Charlene P.; Lorenzón, Esteban Nicolás; Fangueiro, Joana F.; Calpena, Ana Cristina; Chaud, Marco V.; García, María L.; Gremião, Maria Palmira Daflon; Silva, Amélia M.; Souto, Eliana B.

doi:10.1016/j.ijpharm.2014.07.049

Cited by 91 publications

(47 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Formation of a thin PEG layer on the MSN surfaces resulted in slight but statistically significant increase of the particle size from 95 ± 2 nm to 102 ± 4 nm. Moreover, the zeta potential of the particles was decreased from 8.48 ± 0.33 mV to 4.14 ± 0.42 mV at pH 7.0, probably due to the coverage of surface reactive groups, which act as anchors for PEG conjugation [19].…”

Section: Materials Characterisationmentioning

confidence: 97%

Low-melting-point polymeric nanoshells for thermal-triggered drug release under hyperthermia condition

Dabbagh

Mahmoodian

Abdullah

et al. 2015

International Journal of Hyperthermia

View full text Add to dashboard Cite

Purpose: The aim of this paper was to synthesise core-shell nanostructures comprised of mesoporous silica core and a low melting-point polyethylene glycol (PEG) nanoshell with a sharp gel-liquid phase transition for rapid drug release at hyperthermia temperature range. Materials and methods:The phase transition behaviours of PEGs with molecular weights of 1000, 1500, and 2000 Da were analysed using differential scanning calorimetry (DSC) to determine the optimal formulation with phase transition in the hyperthermia range. The 'graftto' method was employed to synthesise core-shell nanostructures using the selected PEG formulation. The drug loading and release behaviours of these nanocarriers were examined by ultra-violet visible spectroscopy (UV-Vis) using doxorubicin as a model drug. Magnetic resonance-guided focused ultrasound (MRgFUS) was also applied as a typical thermal modality to evaluate the rate of drug release from the core-shell nanostructures. Results: The PEG molecular weight of 1500 Da presented the optimal phase transition temperature for thermaltriggered release under hyperthermia conditions. Drug release measurements at different temperatures using UV-Vis methods showed a 20.2 ± 4.3% leakage in aqueous solution at 37 C after 30 min, while this value was significantly increased to 68.2 ± 3.7% at 50 C. A 45.5 ± 3.1% drug release was also obtained after sonication of the drug-loaded nanoparticles for 5 Â 20 s using MRgFUS. Conclusion: Although the ratio of drug leakage at physiological temperatures was relatively high, the sharp transition temperature, high loading efficiency, and fast drug release at hyperthermia temperature range could make these core-shell nanoparticles prominent for enhancing the efficacy of various hyperthermia modalities in the treatment of cancer tumours.

show abstract

Section: Materials Characterisationmentioning

confidence: 97%

Low-melting-point polymeric nanoshells for thermal-triggered drug release under hyperthermia condition

Dabbagh

Mahmoodian

Abdullah

et al. 2015

International Journal of Hyperthermia

View full text Add to dashboard Cite

show abstract

“…Grafting of poly (ethylene glycol) (PEG) to solid surfaces has also been recognized as a technique to obtain low protein adsorption and low cell adhesion characteristics due to its high hydrophilicity, which impart flexibility and mobility in the aqueous environment [8][9][10]. These modified silica NPs can reduce the likelihood of many medically undesirable processes.…”

Section: Introductionmentioning

confidence: 99%

Synthesis of poly(ethylene glycol) (PEG) grafted silica nanoparticles with a minimum adhesion of proteins via one-pot one-step method

Akbari

Yegani

Pourabbas

2015

Colloids and Surfaces A: Physicochemical and Engineering Aspect

View full text Add to dashboard Cite

“…The exceptional, unique, and singular characteristics of nanopharmaceuticals are associated with their size, matrix composition, and surface properties [4,5,11,[40][41][42][43]. As such, the current legislation must suffer a shift to attend the needs of these new types of pharmaceuticals as these are not approachable with the current regulation applied to health products.…”

Section: Good Manufacturing Practices Applied To Nanopharmaceuticalsmentioning

confidence: 99%

Nanopharmaceutics: Part I—Clinical Trials Legislation and Good Manufacturing Practices (GMP) of Nanotherapeutics in the EU

et al. 2020

Self Cite

View full text Add to dashboard Cite

The latest advances in pharmaceutical technology are leading to the development of cutting edged approaches to produce what is now known as the “Holy Grail” of medicine—nanopharmaceutics. Over the latest decade, the pharmaceutical industry has made important contributions to the scale up of these new products. To ensure their quality, efficacy, and safety for human use, clinical trials are mandatory. Yet, regulation regarding nanopharmaceuticals is still limited with a set of guidelines being recently released with respect to compliance with quality and safety. For the coming years, updates on regulatory issues about nanopharmaceuticals and their use in clinical settings are expected. The use of nanopharmaceuticals in clinical trials depends on the approval of the production methods and assurance of the quality of the final product by implementation and verification of the good manufacturing practices (GMP). This review addresses the available legislation on nanopharmaceuticals within the European Union (EU), the GMP that should be followed for their production, and the current challenges encountered in clinical trials of these new formulations. The singular properties of nanopharmaceuticals over their bulk counterparts are associated with their size, matrix composition, and surface properties. To understand their relevance, four main clinical trial guidelines, namely, for intravenous iron-based nanopharmaceuticals, liposomal-based nanopharmaceuticals, block copolymer micelle-based nanopharmaceuticals, and related to surface coating requirements, are described here.

show abstract

Preparation and characterization of PEG-coated silica nanoparticles for oral insulin delivery

Cited by 91 publications

References 36 publications

Low-melting-point polymeric nanoshells for thermal-triggered drug release under hyperthermia condition

Low-melting-point polymeric nanoshells for thermal-triggered drug release under hyperthermia condition

Synthesis of poly(ethylene glycol) (PEG) grafted silica nanoparticles with a minimum adhesion of proteins via one-pot one-step method

Nanopharmaceutics: Part I—Clinical Trials Legislation and Good Manufacturing Practices (GMP) of Nanotherapeutics in the EU

Contact Info

Product

Resources

About